United Therapeutics Corporation (UTHR) : Summit Street Capital Management scooped up 11,851 additional shares in United Therapeutics Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 26,851 shares of United Therapeutics Corporation which is valued at $3,361,477.United Therapeutics Corporation makes up approximately 3.52% of Summit Street Capital Management’s portfolio.
Other Hedge Funds, Including , Capstone Investment Advisors boosted its stake in UTHR in the latest quarter, The investment management firm added 4,807 additional shares and now holds a total of 8,807 shares of United Therapeutics Corporation which is valued at $1,102,548. United Therapeutics Corporation makes up approx 0.08% of Capstone Investment Advisors’s portfolio.Hsbc Holdings Plc boosted its stake in UTHR in the latest quarter, The investment management firm added 34,040 additional shares and now holds a total of 105,421 shares of United Therapeutics Corporation which is valued at $13,197,655. United Therapeutics Corporation makes up approx 0.04% of Hsbc Holdings Plc’s portfolio.Credit Suisse Ag reduced its stake in UTHR by selling 3,544 shares or 2.56% in the most recent quarter. The Hedge Fund company now holds 135,111 shares of UTHR which is valued at $16,914,546. United Therapeutics Corporation makes up approx 0.02% of Credit Suisse Ag’s portfolio.Blackrock Japan Ltd reduced its stake in UTHR by selling 5,647 shares or 6.63% in the most recent quarter. The Hedge Fund company now holds 79,474 shares of UTHR which is valued at $9,949,350. United Therapeutics Corporation makes up approx 0.03% of Blackrock Japan Ltd’s portfolio. Legacy Capital Partners sold out all of its stake in UTHR during the most recent quarter. The investment firm sold 5,395 shares of UTHR which is valued $689,643.
United Therapeutics Corporation opened for trading at $122.75 and hit $123.47 on the upside on Thursday, eventually ending the session at $123.21, with a gain of 0.76% or 0.93 points. The heightened volatility saw the trading volume jump to 4,20,082 shares. Company has a market cap of $5,356 M.
On the company’s financial health, United Therapeutics Corporation reported $4.55 EPS for the quarter, beating the analyst consensus estimate by $ 1.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $3.52. The company had revenue of $412.60 million for the quarter, compared to analysts expectations of $395.00 million. The company’s revenue was up 18.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.55 EPS.
Many Wall Street Analysts have commented on United Therapeutics Corporation. Shares were Downgraded by H.C. Wainwright on Jun 15, 2016 to ” Neutral” and Lowered the Price Target to $ 95 from a previous price target of $175 .
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.